Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Cellectis S.A. (NASDAQ: CLLS).

Full DD Report for CLLS

You must become a subscriber to view this report.


Recent News from (NASDAQ: CLLS)

Bluebird Bio: Gene Therapy Best In Class
I can confirm that we're at the early stages of a transformation in medical treatment as a consequence of this new technology. FDA commissioner Scott Gottlieb oral testimony This article is part of a series on genomic medicine which is poised to transform healthcare over the next two...
Source: SeekingAlpha
Date: May, 16 2018 11:31
Calyxt down 6% on launching follow-on offering
Cellectis S.A. (NASDAQ: CLLS ) and Calyxt (NASDAQ: CLXT ) announces that Calyxt has commenced a follow-on public offering of 3.05M shares of common stock. More news on: Cellectis S.A., Calyxt, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: May, 16 2018 07:02
Calyxt Announces Launch of Proposed Follow-On Offering
Regulatory News: Cellectis S.A. (Paris:ALCLS) (NASDAQ:CLLS) (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) and Calyxt, Inc. (NASDAQ: CLXT) announced today that Calyxt has commenced a follow-on public offering of 3,050,000 shares of Calyxt’s common stock pursuant to a registration ...
Source: Business Wire
Date: May, 15 2018 17:50
Key events next week - healthcare
Noteworthy events during the week of May 13 - 19 for healthcare investors: More news on: Ovid Therapeutics Inc., Evolus, Inc., Allergan plc, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 11 2018 12:02
Cellectis to Present Data at the 2018 ASGCT Annual Meeting
Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that three posters regarding the Company...
Source: Business Wire
Date: May, 10 2018 17:15
Wired News - Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration with MSK to Develop Next-Generation CAR T Technologies
Stock Monitor: Cellectis Post Earnings Reporting LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want access to our free research report on Atara Biotherapeutics, Inc. (NASDAQ: ATRA ) ("Atara"), all you need to do is sign up now by clicking the following link www.active-investors.co...
Source: ACCESSWIRE IA
Date: May, 10 2018 07:30
Cellectis EPS of -$0.39
Cellectis (NASDAQ: CLLS ): Q1 EPS of -$0.39 may not be comparable to consensus of -$0.70. More news on: Cellectis S.A., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 07 2018 16:44
Cellectis Reports 1st Quarter 2018 Financial Results
IND filed for UCART22 clinical investigation in ALL patients Allogene takes over Pfizer’s rights under the Research and License Agreement with Cellectis, to accelerate development and commercialization of allogeneic off-the-shelf UCART therapies Harvard’s Wyss Institu...
Source: Business Wire
Date: May, 07 2018 16:30
Cellectis Files IND for UCART22 in Acute Lymphoblastic Leukemia (B-ALL)
This is the 3 rd IND filing for a TALEN®-based Gene Edited Allogeneic UCART Product Candidate Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunoth...
Source: Business Wire
Date: May, 02 2018 16:30
Harvard's Wyss Institute partners with Cellectis to recode the human genome
BOSTON and NEW YORK , May 1, 2018 /PRNewswire-USNewswire/ -- Today the Wyss Institute for Biologically Inspired Engineering at Harvard University and Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunothe...
Source: PR Newswire
Date: May, 01 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1828.5529.4929.7228.5364158,903
2018-05-1728.5529.4929.7228.5364158,053
2017-02-0218.4018.32518.5018.2543,251
2017-02-0118.1918.5018.64718.1657,216
2017-01-3117.5418.2418.4717.4299,352

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-1833,65362,37153.9562Short
2018-05-1736,94362,36859.2339Short
2018-05-1620,00228,54270.0792Short
2018-05-1511,39461,73818.4554Cover
2018-05-1415,589111,12614.0282Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CLLS.


About Cellectis S.A. (NASDAQ: CLLS)

Logo for Cellectis S.A. (NASDAQ: CLLS)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: CLLS)

      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 10 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 09 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 07 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 07 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 02 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 01 2018
      Post-effective amendment to an S-8 filing
      Filing Type: S-8 POSFiling Source: edgar
      Filing Date: April, 13 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 11 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 10 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 10 2018

       

       


      Daily Technical Chart for (NASDAQ: CLLS)

      Daily Technical Chart for (NASDAQ: CLLS)


      Stay tuned for daily updates and more on (NASDAQ: CLLS)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: CLLS)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      The Subway Trader
      @TheSubwayTrader

       

       


      Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CLLS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of CLLS and does not buy, sell, or trade any shares of CLLS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/